Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases - the longer the less? Authors' reply

Aliment Pharmacol Ther. 2022 Jan;55(2):246. doi: 10.1111/apt.16722.

Authors

Johannes P D Schultheiss¹, Remi Mahmoud¹, Herma H Fidder¹, Bas Oldenburg¹

Affiliation

¹ Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.

PMID: 34970765
DOI: 10.1111/apt.16722

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Inflammatory Bowel Diseases* / drug therapy